Celltrion Launches Remsima SC (biosimilar, infliximab) for Rheumatoid Arthritis in Canada

Shots:

Celltrion launches the world’s first SC formulation of infliximab (120mg, q2w, fd, as a pre-filled pen (auto-injector) in Canada for the treatment of adult patients with RA
Remsima SC will be the first product to be commercially available in Canada under the new direct sales marketing strategy and is supported by the CELLTRION CONNECT patient support program
The biosimilar is approved in Canada for use in combination with MTX to reduce the signs and symptoms, inhibit the progression of structural damage and improvement in physical function in adult patients with RA

Click here to read full press release/ article | Ref: Celltrion | Image: Celltrion